Effect of Atorvastatin on Cognitive Function in Patients from the Lipid Lowering and Onset of Renal Disease (LORD) Trial

Mathew J Summers; K R Oliver; J S Coombes; R G Fassett

doi:10.1592/phco.27.2.183

Back

Effect of Atorvastatin on Cognitive Function in Patients from the Lipid Lowering and Onset of Renal Disease (LORD) Trial

Journal article

Peer reviewed

Effect of Atorvastatin on Cognitive Function in Patients from the Lipid Lowering and Onset of Renal Disease (LORD) Trial

Mathew J Summers, K R Oliver, J S Coombes and R G Fassett

Pharmacotherapy: the journal of human pharmacology and drug therapy, Vol.27(2), pp.183-190

2007

DOI: https://doi.org/10.1592/phco.27.2.183

Files and links (1)

url

https://doi.org/10.1592/phco.27.2.183View

Published Version

Abstract

Pharmacology and Pharmaceutical Sciences

attention

concentration

atorvastatin

statins

cognition

renal disease

Study Objective. To examine the effect of atorvastatin on cognitive function by testing two hypotheses: that atorvastatin 10 mg/day would impair cognitive function, and that other biochemical and demographic measures would better predict cognitive performance than atorvastatin alone. Design. Randomized, double-blind, placebo-controlled study. Setting. Two primary acute care settings in the north and northwest of Tasmania, Australia. Patients. Fifty-seven patients from the Lipid Lowering and Onset of Renal Disease (LORD) trial. Intervention. Participants were randomly assigned to receive either atorvastatin 10 mg/day or matching placebo. Cognitive testing was performed in two sessions occurring 12 weeks apart and involved three repeated measures of attention and concentration. Measurements and Main Results. Performance was measured using three standard neuropsychological tests: Digit Symbol Coding subtest, Trail Making Test, and Stroop Color-Word Reading Test. Patients received atorvastatin for a mean of 72.93 weeks and placebo for a mean of 68.85 weeks. Repeated-measures multivariate analysis of variance failed to identify any significant differences between the two groups on any of the three cognitive measures. Multiple regression analyses identified no single factor or combination of plasma cholesterol levels, renal function, liver function, or age that predicted cognitive performance in either the atorvastatin or placebo group on the three measures at either testing session. Conclusion. Atorvastatin 10 mg/day did not produce decrements to cognitive performance. In addition, biochemical and demographic measures and the receipt of atorvastatin versus placebo did not individually or in combination predict cognitive performance on measures of attention and concentration.

Details

Title: Effect of Atorvastatin on Cognitive Function in Patients from the Lipid Lowering and Onset of Renal Disease (LORD) Trial
Authors: Mathew J Summers (Author) - University of Tasmania
K R Oliver (Author) - University of Tasmania
J S Coombes (Author) - University of Queensland
R G Fassett (Author) - Launceston General Hospital
Publication details: Pharmacotherapy: the journal of human pharmacology and drug therapy, Vol.27(2), pp.183-190
Publisher: John Wiley & Sons Inc.
Date published: 2007
DOI: 10.1592/phco.27.2.183
ISSN: 0277-0008
Organisation Unit: School of Health; School of Social Sciences - Legacy; University of the Sunshine Coast, Queensland; School of Health - Psychology; School of Health and Behavioural Sciences - Legacy
Language: English
Record Identifier: 99451141302621
Output Type: Journal article

Metrics

1 File views/ downloads

368 Record Views

34 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration
Web Of Science research areas: Pharmacology & Pharmacy

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites